This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Download the free report today for data-driven insights into RWD. Please check your inbox to download the Report. Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurancecoverage or access.
Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. In order to automate and enhance these tasks, AI-driven NLP can assist.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Topic sponsors are not involved in the creation of editorial content.
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.
4] One of the key things to note is that this gene variation also prevents people from properly methylating, which is one of the body’s key detox processes that helps them get rid of toxins. However, some may be concerned with this genetic information getting reported on insurance or to employers.
Unlike the abundance of freely downloadable wellbeing apps, DTx products are meant to be prescribed for a therapeutic indication and potentially eligible for reimbursement by national health services subject to health technology assessment studies.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.
Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.
Note: To help you even further, I’ve created an eBook, Optimizing Thyroid Medications , that you can download for free.) Learn more about LDN and download the full transcript of my interview with Dr. Mark Mandel below! It’s a process and a journey, but it’s definitely worth it. You fit the pieces together to complete the puzzle.
Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.
Too often the formal notice and comment process does not reach these marginalized communities and federal agencies must actively work to seek their input in non-traditional ways. This process respects their autonomy by involving them in decision-making to the extent that they are able.
Pharmacy has drastically changed, and with the patient view of most pharmacists just 'Count-Lick-and Pour' medications for patients it's not hard then to think of how to just automate the process. One issue is that the dispensing process is not a full-proof system at the current time. Download Image.
This alliance seeks to bolster clinical trial capabilities through improved regulatory processes and data governance. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Don’t let policy changes catch you off guard.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. You will receive an email shortly.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. JCR has also developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo, to deliver biotherapeutics into the central nervous system. You will receive an email shortly.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. AbbVie’s purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector’s outlook.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. This update also suggests we may not see REMS requirements for CD19 and BCMA autologous CAR-T cell therapies in the future,” the research note added. You will receive an email shortly.
Fast-Tracking the Future Nicholas Saraceno, Editor ; Don Tracy, Associate Editor April 25th 2025 Podcast Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework. Click here to view our interactive June 2025 issue!
Porton Advanced will apply its knowledge in viral vector technology and CAR-T cell therapy process development to enhance EVA Pharma’s mission to provide safe, effective, and scalable cancer treatments. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. You will receive an email shortly.
These platforms are designed for safe drug production while allowing scaleable manufacturing processes. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. You will receive an email shortly.
Mackey says that people may seek medications due to issues with health insurance policies, variable coverage for certain conditions, lack of access, and more. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.
I’ll specify which tests are usually covered on insurance if you have a willing practitioner that can bill insurance, which tests can be self-ordered and then submitted to insurance, and which ones are usually an out-of-pocket expense that you may need to save for. You can use Health Savings Accounts for most.)
They also experience some of the same problems that manufacturers and distributors face, like spotty tracking information due to the manual processes associated with barcode scanning of drugs. Large hospital systems, for example, have medications distributed among many different pharmacies and departments. References 1. FDA at a Glance.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Elsewhere in the partnership arena, AstraZeneca outlaid $5.2bn to enlist the services of China-based CSPC Pharmaceuticals. Topic sponsors are not involved in the creation of editorial content.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. You will receive an email shortly.
The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers. Koseff A, Hwang K.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content